Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasminogen is a glycoprotein zymogen that serves as the precursor to plasmin, a serine protease responsible for fibrinolysis. It is produced in the liver and circulates in the blood. Activation of plasminogen by tPA or uPA leads to the degradation of fibrin clots and other extracellular matrix proteins. Dysregulation of plasminogen activity can result in thrombotic or bleeding disorders, and it plays a role in cancer metastasis, inflammation, and tissue remodeling. Therapeutic strategies target this pathway through thrombolytic agents or antifibrinolytic therapies.
tPA and uPA analogs promote the conversion of plasminogen to plasmin, leading to clot dissolution. Antifibrinolytic agents inhibit plasminogen activation or plasmin activity, preventing clot breakdown.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasminogen (None).